Valeant and its ally, Pershing Square, lost the battle to acquire Allergan. Sometimes, the losers in a takeover battle can also win if they own a toehold stake in the targets stock. Between April and June 2014, Pershing acquired a 10.90% stake in Allergan at an estimated average price of $152 a share. In November, Actavis offered $231 per share for each of Allergans 419 million shares. What was Pershings profit on its holding? (Do not round intermediate calculations. Enter your answer in millions rounded to 1 decimal place.)